Phase III Failure Leaves Cytokinetics with One Last Late-Stage Hopeful

Cytokinetics is discontinuing the Phase III COURAGE-ALS trial in amyotrophic lateral sclerosis after its candidate reldesemtiv failed a planned interim analysis, the company announced Friday.